Q-omics provides the consensus-scored C17orf97 profile across patient tissues and cancer cell-line models. C17orf97 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C17orf97 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, C17orf97 RNA expression shows 13,493 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KICH as cancer lineages where C17orf97 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf97 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf97 survival associations across molecular data types. C17orf97 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf97 RNA expression–survival associations across cancer types. High C17orf97 expression shows unfavorable associations in ACC, but favorable associations in KIRP, UCEC, READ, THCA and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for C17orf97 RNA expression.
This table summarizes C17orf97 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C17orf97. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf97 shows lower tumor expression in KICH, THCA, COAD and LUSC and higher tumor expression in KIRP and BRCA. The KICH box plot shows higher C17orf97 RNA expression in normal versus tumor tissue (log2 FC = −1.733, t-test p < 0.001).
This table shows molecular features associated with C17orf97 in patient tissues and cancer cell lines. In patient samples, C17orf97 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf97 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
